EyePoint: Phase 3 Design Creates A More Valuable Durability Story (NASDAQ:EYPT)
· seekingalpha.com
EyePoint nears a binary catalyst: Phase III LUGANO DURAVYU wet AMD data in Aug. 2026. Click here to read more about the EYPT stock.
My optimism about EyePoint ( EYPT ) rests on more than the possibility that DURAVYU will reduce injection frequency in retinal diseases. More importantly, EyePo...